Synopsis: A systematic review and meta-analysis revealed that the use of prophylactic, long-term macrolides reduces the rate of acute exacerbations in patients with bronchiectasis. This is true across many subgroups including in patients with pseudomonal infection for which current guidelines do not recommend the use of macrolides.
Source: Chalmers JD, Boersma W, Lonergan M, et al. Long term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respir Med. 2019;7:860–869.